The Global Health Body Issues Alert Over Severe Shortage of Obesity Jabs
Under a tenth of patients that would benefit from weight-loss injections like Wegovy can access them, states the WHO as it releases its inaugural advice on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for more widespread and fairer availability to this class of drugs.
Based on estimates, over two billion could be obese by 2030 if no action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be managed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant obstacles to universal availability to the treatments that can assist patients in reducing considerable body mass, explains the body.
GLP-1 Therapy Scarcity
Despite the present best projected scenario, the supply of such drugs would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The advice calls on governments and firms to widen availability, through strategies including voluntary licensing.
A patent on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Jabs Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so users consume fewer calories.
Patients commonly see weight reduction within a few weeks of starting on the weekly injections.
Studies suggests patients may see weight return within a year of discontinuing the treatment, because their normal appetite return.
To be overweight or obese increases your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns people in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
